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Background: LRP1 is an endocytic receptor of ADAMTS-5 (aggrecanase 2) in cartilage.
Results: ADAMTS-4 (aggrecanase 1) is also internalized via LRP1 but at a slower rate than ADAMTS-5.
Conclusion: LRP1 differently regulates the extracellular activities of the two key aggrecanases in cartilage.
Significance: LRP1 is a major traffic controller of the two aggrecanases.
Degradation of the cartilage proteoglycan aggrecan is an
early event in the development of osteoarthritis, and a disin-
tegrin and metalloproteinase with thrombospondin motifs-4
(ADAMTS-4) and ADAMTS-5 are considered to be the major
aggrecan-degrading enzymes. We have recently found that
ADAMTS-5 is rapidly endocytosed via low density lipoprotein
receptor-related protein 1 (LRP1) and degraded by chondro-
cytes. Here we report that this regulatory mechanism also
applies to ADAMTS-4, although its rate of endocytosis is slower
than that of ADAMTS-5. Domain deletion mutagenesis of
ADAMTS-4 identified that the cysteine-rich and spacer
domains are responsible for binding to LRP1, whereas the
thrombospondin 1 and spacer domains are responsible in
ADAMTS-5. The estimated t1⁄2 value of ADAMTS-4 endocytosis
was about 220 min, whereas that of ADAMTS-5 was 100 min.
The difference in half-lives between the two enzymes is
explained by the 13-fold lower affinity of ADAMTS-4 for LRP1
comparedwith that of ADAMTS-5. Studies using soluble ligand
binding clusters of LRP1 showed that ADAMTS-4 binds to clus-
ters II and IVwith similarKD,app values of 98 and 73 nM, respec-
tively, whereas ADAMTS-5 binds to cluster II, III, and IV
with KD,app values of 3.5, 41, and 9 nM, respectively. Thus,
ADAMTS-5 competitively inhibits ADAMTS-4 endocytosis
but not vice versa. This studyhighlights that the affinity between
a ligand and LRP1 dictates the rate of internalization and sug-
gests that LRP1 is a major traffic controller of the two aggreca-
nases, especially under inflammatory conditions, where the pro-
tein levels of ADAMTS-4 increase, but those of ADAMTS-5 do
not.
Aggrecan is amajor extracellular matrix component of artic-
ular cartilage, and its degradation is an early event in the devel-
opment of osteoarthritis (OA)6 (1–3). The major proteinases
responsible for aggrecan degradation are matrix metallopro-
teinases (MMPs) and aggrecanases that are members of a dis-
integrin and metalloproteinase with thrombospondin motifs
(ADAMTS) family (4). Aggrecanases are defined by their ability
to cleave the Glu373-Ala374 bond of the aggrecan core protein
(5, 6). Elevated aggrecanase-generated aggrecan fragments
have been found in synovial fluids of patients with OA and
inflammatory joint disease (7, 8). These fragments were also
detected in normal synovial fluid and serum of animals (6),
suggesting that aggrecanases function in both physiological and
pathological catabolismof aggrecan.Among theADAMTS that
have aggrecanolytic activity, ADAMTS-4 and ADAMTS-5
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have been considered as the major aggrecanases involved in
cartilage matrix turnover because of their effective aggre-
can-degrading activity in vitro (9–11). Although mouse gene
ablation studies have indicated ADAMTS-5 is the key aggreca-
nase for the development of arthritis in mice (12–14), both
ADAMTS-4 and ADAMTS-5 are considered to play roles in
humanOA (15, 16). ADAMTS-5 is about 30more active than
ADAMTS-4 on aggrecan (11), but we have recently found that
it is rapidly endocytosed by chondrocytes via the scavenger
receptor low density lipoprotein receptor-related protein 1
(LRP1). This suggests that the post-translational regulation is a
major regulatory mechanism of the extracellular levels of
ADAMTS-5, and this regulation is impaired in OA cartilage
due to the reduction in LRP1 levels largely caused by shedding
from the cell membrane (17). This in part explains an increased
extracellular activity of ADAMTS-5 and aggrecan degradation
leading to slowly progressing OA in which little significant
increase in ADAMTS-5 mRNA was observed (15, 18, 19). In
contrast, the expression of ADAMTS-4 mRNA and its protein
levels correlate with the progression of OA in humans (15).
LRP1 is a multifunctional endocytic type 1 transmembrane
receptor consisting of a 515-kDa -chain containing the extra-
cellular ligand binding domains and a non-covalently associ-
ated 85-kDa -chain containing a transmembrane domain and
a short cytoplasmic tail (20). LRP1 internalizes 40 ligands
from the pericellular environment, including lipoproteins,
extracellular matrix (ECM) proteins, growth factors, cell sur-
face receptors, proteinases, andproteinase-proteinase inhibitor
complexes (21–23). LRP1 is widely expressed (24, 25), and its
expression is particularly high in articular chondrocytes and
macrophages.7 The ablation of the LRP1 gene inmice is embry-
onically lethal (26), but tissue specific deletion of the LRP1 gene
has demonstrated that it protects the vasculature and controls
-amyloid precursor protein trafficking, lipid metabolism in
adipocytes, and macrophage biology (27). In cartilage, LRP1
can endocytose MMP-13 (28, 29) and tissue inhibitor of metal-
loproteinases (TIMP-3), which inhibits collagenases and aggre-
canases (30, 31). LRP1 interacts with frizzled-1 and down-reg-
ulates the canonical Wnt--catenin signaling pathway (32). It
also represses the hypertrophy of chondrocytes during endo-
chondral ossification by removing connective tissue growth
factor (33, 34). LRP1 is, therefore, an important regulator
of skeletal development and maintenance of cartilage
homeostasis.
In this study we have re-addressed whether ADAMTS-4,
which has a similar homologous domain composition to
ADAMTS-5, is endocytosed by chondrocytes by either the
samemechanismor by different pathways. The initial discovery
ofADAMTS-5 endocytosis stemmed fromour observation that
aggrecanase activity is reduced when ADAMTS-5 was incu-
bated with live porcine cartilage compared with when it was
incubated with freeze-thawed (dead) cartilage. This led us to
discover that ADAMTS-5 is endocytosed via LRP1 by viable
chondrocytes. In those studies we observed no significant dif-
ferences in aggrecan degradation between live and dead carti-
lage when ADAMTS-4, MMP-1, or MMP-13 was added (17),
although MMP-13 has been reported to be endocytosed by
chondrocytes via LRP1 (28, 29).However, the concentrations of
ADAMTS-4 and MMP-13 used in those studies were 10-fold
higher than that of ADAMTS-5, as ADAMTS-5 is the most
active aggrecanase (10, 11). Furthermore, we noticed that the
basal level of aggrecan degradation in live cartilage was slightly
but significantly higher than that of dead cartilage. Subtraction
of these values from those in which ADAMTS-4 was added
revealed a significant reduction in aggrecanolytic activity
detected with live cartilage compared with that with dead car-
tilage, and this difference is more prominent at lower concen-
trations of ADAMTS-4. The present study demonstrates bona
fide LRP1-mediated endocytosis of ADAMTS-4. We also show
the similarities and differences in LRP1 interaction between
ADAMTS-4 and ADAMTS-5. Our endocytic competition
studies between the two aggrecanases provide further insights
into their role in normal turnover and pathological degradation
of aggrecan.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies—The sources of materials used
were as follows: dimethylmethylene blue and the anti-FLAG
M2 mouse monoclonal antibody from Sigma; BC-3 mouse
monoclonal antibody that recognizes the N-terminal
374ARGSV aggrecan core protein fragments generated by
aggrecanase, the anti-early endosome antigen 1 (EEA1) rabbit
polyclonal antibody, and the anti-LRP1 mouse monoclonal
antibodies 5A6 and 8G1 from Abcam (Cambridge, UK) and
from Calbiochem; a hydroxamate-based MMP inhibitor
CT-1746 from Celltech (Slough, UK); the anti-actin antibody
from Santa Cruz Biotechnology (Santa Cruz, CA); the anti-tu-
bulin antibody from Cell Signaling (Danvers, MA); the anti-
Myc tag antibody from Merck Millipore (Darmstadt, Germa-
ny); purified human full-length LRP1 from BioMac (Leipzig,
Germany). The anti-human ADAMTS-4 catalytic domain rab-
bit polyclonal antibody was raised in rabbit and characterized
(9). Recombinant human ADAMTS-4, ADAMTS-5, their
domain deletion mutants, MMP-1, MMP-13, and RAP were
prepared as described previously (9, 10, 35, 36). Recombinant
human IL-1 was kindly provided by Prof. J. Saklatvala (Ken-
nedy Institute of Rheumatology, Oxford, UK). All other
reagents used were of the highest analytical grade available.
Human and Porcine Articular Cartilage Culture—Human
articular cartilage was obtained from patients undergoing
amputations at the RoyalNationalOrthopaedicHospital (Stan-
more, UK) following informed consent and approval by the
Riverside Research Ethics Committee. Healthy cartilage was
obtained from the knee after amputation due to soft tissue sar-
coma and osteosarcoma with no involvement of the cartilage.
Tissues were obtained from 5 patients (all male; aged 8–41
years, mean age 21.2 years).
Dissected human articular cartilage (20 mm3: 25 mg wet
volume/weight) or porcine articular cartilage (6 mm3: 10 mg
wet volume/weight) from the metacarpophalangeal joints of
3–9-month-old pigs was placed in one well of a round-bottom
96-well plate and allowed to rest for 24 h in 200l of Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal bovine7 K. Yamamoto, unpublished results.
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serum before use. The medium was then replaced, and the car-
tilage was rested for a further 24 h in 200 l of DMEM at 37 °C
(for fresh live cartilage) before aggrecan degradation and endo-
cytosis assays. For freeze-thawed cartilage experiments, carti-
lage pieces were frozen at 80 °C and thawed in the same
medium to render the chondrocytes non-viable. The medium
was replaced with fresh medium before subsequent assays.
Analysis of Aggrecan Degradation—Each piece of cartilage
was incubated in 100 l of DMEM with or without IL-1 (10
ng/ml) or various concentrations of MMPs and ADAMTS.
Three pieces of cartilage were subjected to each treatment.
After incubation for various periods of time, the conditioned
media were harvested and glycosaminoglycan (GAG) released
into the medium was measured using the dimethylmethylene
blue assay (37). Aggrecan fragments in themediumwere degly-
cosylated as described previously (9) and analyzed by Western
blotting using an anti-ARGSV aggrecan neoepitope antibody
(BC-3). Immunoreactive bands were quantified using NIH
ImageJ, and results are presented as relative intensities.
Isolation of Chondrocytes and Cell Culture—Chondrocytes
were isolated as described previously (31). Primary porcine cells
and both primary and passaged human cells were used in the
experiments. For the endocytosis assay, cells were plated at a
density of 2.5  105 cells/well (24-well plate) in DMEM con-
taining 10% FCS.
Analysis of ADAMTS-4 Clearance—Cartilage explants or
cells were incubated in 100 or 400l of DMEMwith or without
500 nM RAP. After incubation for 30 min, media were replaced
with DMEM containing 10 nM ADAMTS-4 or its domain dele-
tion mutants with or without 500 nM RAP. Four pieces of car-
tilage were subjected to each treatment. After incubation for
various periods of time, media were collected, and the protein
was precipitated with TCA and dissolved in 50 l of 1 SDS-
sample buffer (50 mM Tris-HCl (pH 6.8), 5% 2-mercaptoetha-
nol, 2% SDS, and 10% glycerol). The cartilage explants and cells
were washed with DMEM and lysed in 50 l of 2 SDS sample
buffer. All samples were analyzed by SDS-PAGE and Western
blotting using an anti-ADAMTS-4 catalytic domain antibody.
Immunoreactive bands were quantified using NIH ImageJ, and
the amount of ADAMTS-4 remaining in the medium at each
time point was calculated as a percentage of the amount of
ADAMTS-4 at 0 h. The amount of ADAMTS-4 incubated
alone in the medium at each time point was also calculated as
described above, and each value was normalized by subtracting
the amount of auto-degraded ADAMTS-4 at each time point.
Immunocytochemical Localization of Endocytosed ADAMTS-4—
Cultured cells on 4-well Lab-Tek chamber slides (Nunc, Rosk-
ilde, Denmark) were incubated in DMEM with 20 nM
ADAMTS-4 in the absence or presence of 500 nM RAP for 4 h.
Cells were washed with DMEM, fixed with 3% paraformalde-
hyde in Tris-buffered saline (TBS; 10 min, room temperature),
and permeabilized with TBS containing 10 mM CaCl2 (TNC)
and 0.1% Triton X-100 (15min, room temperature). Each sam-
ple was incubatedwith anti-FLAGM2mousemonoclonal anti-
body and anti-EEA1 rabbit polyclonal antibody (3 h, room tem-
perature). Alexa Fluor 488-conjugated anti-mouse IgG and
Alexa Fluor 568-conjugated anti-rabbit IgG (Molecular Probes,
Eugene, OR) were used to visualize the antigen signals (1 h,
room temperature). Actin was stained with actin stain 670
phalloidin (Cell Signaling), and nuclei were stained with DAPI.
Samples were viewed using aNikon Eclipse TE2000-U confocal
laser scanningmicroscope. The datawere collated usingVoloc-
ity software (Improvision, Coventry, UK).
siRNA Knockdown of LRP1 in Human Articular Chon-
drocytes—siRNA oligonucleotides for LRP1 (On-TargetPlus
SMARTpool siRNA), and nontargeting oligonucleotide were
purchased from Thermo Scientific Dharmacon (Lafayette,
CO). Human articular chondrocytes were plated at a density of
1.5 106 cells/dish (6-cm dish) in DMEM containing 10% FCS
and incubated until 50% confluent. Lipofectamine 2000 (Invit-
rogen) was used to transfect cells with siRNA at a final concen-
tration of 10 nM in Opti-MEM I. At 4 h after transfection, the
Opti-MEMwas removed and replaced with DMEM containing
10% FCS.
QuantitativeReverseTranscriptase-PCR—Quantitative re-
verse transcriptase-PCR was carried out as described previ-
ously (36). Briefly, cDNA was generated using a reverse-tran-
scription kit (Applied Biosystems, Foster City, CA) and random
primers from RNA were extracted and prepared using the
RNeasymini kit (Qiagen, Valencia, CA) following themanufac-
turer’s guidelines. cDNAwas then used for real time PCR assays
using TaqMan technology. The  threshold cycle (Ct)
method of relative quantitation was used to calculate relative
mRNA levels for each transcript examined. The 60 S acidic
ribosomal protein P0 (RPLP0) gene was used to normalize the
data. Pre-developed primer/probe sets for LRP1 and RPLP0
were purchased from Applied Biosystems.
ELISA for Binding of ADAMTS-4 and ADAMTS-5 to LRP1 or
Soluble LRP1 Fragments—Human LRP1 or soluble LRP1 frag-
ments (5 or 25 nM, respectively, in 100 l of TNC) was coated
overnight at 4 °C onto microtiter plates (Corning). Wells were
blocked with 3% BSA in TNC (1 h; 37 °C) and washed in TNC
containing 0.05% (v/v) Brij-35 after this and each subsequent
step.Wells were then incubated with various concentrations of
ADAMTS-4, its domain deletion mutants, or domain deletion
mutants of ADAMTS-5 in blocking solution containing 100M
CT-1746 for 3 h at room temperature. Bound enzymes were
detected using anti-FLAG M2 mouse monoclonal antibody (1
h; room temperature) and then with an anti-mouse secondary
antibody coupled to horseradish peroxidase (Abcam; 1 h; room
temperature). Hydrolysis of tetramethylbenzidine substrate
(KPL, Gaithersburg, MA) was measured at 450 nm using a
BioTek EL-808 absorbance microplate reader (BioTek, Win-
ooski, VT). Each value was normalized by subtracting the
amount of enzyme bound to control wells that were not coated
with LRP1 or soluble LRP1 fragments.
Expression and Purification of Soluble LRP1 Fragments—The
expression vector for the selected portions (ligand binding
domain clusters I-IV) of LRP1 (see Fig. 7A) has been prepared
previously (38). Secreted fragments of LRP1 containing individ-
ual ligand binding domain cluster were transiently expressed in
HEK293 cells using TransIT-2020 transfection reagent (Mirus,
Madison, WI) according to the manufacture’s protocol. Cells
growing in 150-mmdishes (70%confluence)were transfected
in serum-containing DMEM with 30 g of pSecTagB (Invitro-
gen) carrying cDNA for various LRP1 fragments. After 6 h of
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transfection, the medium was replaced with serum-free
DMEM, and cells were further incubated for 72 h. The resultant
conditioned medium was directly applied to a nickel-nitrilotri-
acetic acid affinity column (Qiagen) that had previously been
equilibrated with 50 mMHEPES (pH 7.5) buffer containing 150
mM NaCl and 5 mM CaCl2. The column was washed with 10
column volumes of 50 mM HEPES (pH 7.5) buffer containing
1 MNaCl, 5 mMCaCl2, and 20mM imidazole. It was then eluted
by 500 mM imidazole in HEPES (pH 7.5) buffer containing 150
mM NaCl and 5 mM CaCl2. For analysis of N-linked glycosyla-
tion of soluble LRP1 fragments, the preparations were treated
with peptide N-glycosidase F (New England Biolabs, Ipswich,
MA) according to the manufacturer’s protocol.
RESULTS
Aggrecanase Activity of ADAMTS-4 Is Reduced in Live Carti-
lage Compared with Dead Cartilage—We first evaluated the
ability of ADAMTS-4 to cleave aggrecan in cartilage by adding
recombinant ADAMTS-4 lacking the C-terminal spacer (Sp)
domain to live or freeze-thawed (dead) porcine cartilage
explants in culture andmeasuringGAG release after 24 h. Dead
cartilage was used to eliminate the involvement of metaboli-
cally active live chondrocytes (36). Live cartilage responded to
IL-1 and released GAG, but this was negligible with dead carti-
lage, indicating that the latter ismetabolically inactive (Fig. 1A).
At 10–50 nM ADAMTS-4, the amount of GAG released from
live cartilage was significantly lower than that released from
dead cartilage; the ratio of GAG release from dead cartilage
compared with live cartilage was 4.7, 3.3, and 1.6 with 10, 20,
and 50 nM ADAMTS-4, respectively. There was no significant
difference inGAG release when 100 nMADAMTS-4was added
(Fig. 1B).Western blot analysis of the products generated by 20
nM ADAMTS-4 with an anti-ARGSV neoepitope antibody
indicated that aggrecan was cleaved at the Glu373-Ala374 bond,
characteristic of aggrecanase activity (Fig. 1C).
ADAMTS-4 Is Internalized and Degraded by Articular Car-
tilage Chondrocytes via LRP—When 10 nM ADAMTS-4 was
added to live cartilage in culture, 75% of the enzyme was
depleted from the medium after 8 h without any detectable
degradation fragments as shown byWestern blot analysis (Fig.
2A and B). In contrast, most of ADAMTS-4 remained in the
medium when exposed to dead cartilage. A small portion of
ADAMTS-4 was also detected in extracts from both live and
dead cartilage after 2–8 h, suggesting its binding to cartilage
ECM.We could not detect endogenousADAMTS-4, as its level
was too low to detect by this method. The addition of RAP, an
antagonist of ligand binding to LRP receptors, to this system
almost completely inhibited ADAMTS-4 depletion from the
medium of live cartilage (Fig. 2B), suggesting that ADAMTS-4
is endocytosed by a member of the LRP family. Isolated chon-
drocytes endocytosed ADAMTS-4 with similar kinetics as live
cartilage (half-life of6 h, and their endocytosis was also inhib-
ited by RAP) (Fig. 2C). The internalization of ADAMTS-4 was
examined by immunofluorescent confocal microscopy, with
punctate staining ofADAMTS-4 observedwithin cells, colocal-
izing with EEA1, a marker for early endosomes (Fig. 2D). Con-
sistent with the data fromWestern blot analysis, the intracellu-
lar fluorescent signal for ADAMTS-4 was abolished in the
presence of RAP. Heparin also blocked the internalization of
ADAMTS-4.
siRNA-mediated Knockdown of LRP1 Impairs ADAMTS-4
Endocytosis in Human Chondrocytes—Among the LRP family,
LRP1 is the major endocytic receptor for proteases and prote-
ase inhibitors (23). Silencing LRP1 in normal human chondro-
cytes by LRP1-targeting siRNA reduced mRNA levels by 92%
compared with the non-targeting siRNA control (Fig. 3A).
Western blot analysis of the cell extracts confirmed that levels
of the 515-kDa extracellular -chain and the 85-kDa -chain
containing the transmembrane domain were reduced by 88
and 81%, respectively (Fig. 3, B and C). Cellular uptake of
ADAMTS-4wasmarkedly reduced in LRP1-depleted cells (Fig.
3D). From these results, we conclude that LRP1 is the primary
endocytic receptor for ADAMTS-4.
Inhibition of ADAMTS-4 Endocytosis by RAP Enhances
Aggrecan Degradation in Articular Cartilage—We then exam-
ined the effect of RAP on ADAMTS-4-mediated aggrecan deg-
radation in cartilage. The addition of 20 nM recombinant
ADAMTS-4 to dead cartilage caused a 2.1-fold higher GAG
release over that from live cartilage after 8 h of incubation, and
it increased to 2.5-fold after 48 h. The addition of RAP to the
ADAMTS-4-mediated aggrecan degradation system signifi-
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FIGURE 1.Aggrecanase activity ofADAMTS-4 is reduced in live comparedwithdead cartilage.A, live and freeze-thawed (Dead) porcine cartilage explants
(n 3)were incubatedwithout orwith 10 ng/ml IL-1 for 24 h. GAG released into themediumwasmeasured by the dimethylmethylene blue assay. B, live and
dead porcine cartilage were incubated with various concentrations of ADAMTS-4 for 24 h. GAG released into the medium was measured as in A. C, densito-
metric analysis of immunoreactive aggrecan fragments detected in themedium after 24 h of culture (from B, 20 nM) byWestern blotting using an anti-ARGSV
neoepitope antibody. The amount of aggrecan fragment in the medium of live cartilage explants incubated with 20 nM ADAMTS-4 was taken as 1. Bars
represent the means S.D. *, p	 0.05; unpaired t test.
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cantly enhanced GAG release from live cartilage but had no
effect on GAG release from dead cartilage (Fig. 4A). Notably,
the level of GAG released from live cartilage in the presence of
RAP was equivalent to that from dead cartilage. Western blot-
ting using an anti-ARGSV antibody confirmed that the 2.1-fold
increase in aggrecan degradation observed in the presence of
RAP is solely due to increased aggrecanase activity of exoge-
nously added ADAMTS-4 in live cartilage (Fig. 4B).
ADAMTS-4-induced aggrecan degradation was also tested
with normal human cartilage. As shown in Fig. 4C, the addition
of 20 nM ADAMTS-4 to dead cartilage caused a 2.3-fold higher
GAG release than that with live cartilage after 24 h of incuba-
tion. The addition of RAP to the ADAMTS-4-mediated aggre-
can degradation system significantly enhanced GAG release
from live human cartilage, but it had no effect with dead
cartilage.
Sp and CysR Domains Mediate ADAMTS-4 Endocytosis—
ADAMTS-4 and ADAMTS-5 are multidomain metallopro-
teinases and have a similar domain arrangement consisting of
pro, catalytic metalloproteinase, disintegrin, TS, CysR and Sp
domains. In addition, ADAMTS-5 contains an extraTSdomain
after the Sp domain.We, therefore, investigatedwhich domains
are required forADAMTS-4 endocytosis by testing endocytosis
of a series of domain-deletion mutants by porcine primary
chondrocytes (Fig. 5A). The half-life (t1⁄2) of ADAMTS-4-1 was
220min (Table 1). Deletion of the Sp domain (ADAMTS-4-2)
significantly reduced the rate of endocytosis with the t1⁄2 of 360
min. Further deletion of the CysR domain (ADAMTS-4-3) and
TS domain (ADAMTS-4-4) reduced endocytosis to negligible
levels. These data were compared with the t1⁄2 values of
ADAMTS-5 and its domain deletion mutants (Fig. 5C and
Table 1). The t1⁄2 values of ADAMTS-4-1 and ADAMTS-4-2
were about 2.2- and 1.6-fold longer than those of the equivalent
domain composition species ADAMTS-5-2 and ADAMTS-
5-3, respectively (Table 1). It is notable that the t1⁄2 value of
ADAMTS-5-4 was250 min, whereas ADAMTS-4-3 was not
internalized even after 480 min. From these data we conclude
that the domains that are responsible for ADAMTS-4 endocy-
tosis are the CysR and Sp domains, whereas those in
ADAMTS-5 are the TS1 and Sp domains. The rate of internal-
ization of full-length ADAMTS-4 was2-fold slower than that
of full-length ADAMTS-5.
ADAMTS-4 and ADAMTS-5 Directly Bind to LRP1 via Dif-
ferent Non-catalytic Domains—The effect of the non-catalytic
domains of ADAMTS-4 on direct binding to LRP1 was investi-
gated by a solid-phase binding assay using domain deletion
mutants. Similar domain deletionmutants of ADAMTS-5were
also tested and compared. It was only possible to conduct lim-
ited experiments with ADAMTS-4-1, as only small amounts
can be purified, but an extrapolated apparent binding constant
(KD,app) of 51 nMwas calculated similar to that ofADAMTS-5-3
(KD,app 56 nM) (Fig. 6 and Table 1). ADAMTS-4-2 bound to
immobilized LRP1 with a KD,app of 110 nM and further deletion
of CysR domain (ADAMTS-4-3) abolished the binding to
LRP1.On the other hand, ADAMTS-5-2 bound to immobilized
LRP1 with a KD,app of 3.8 nM and ADAMTS-5-4, which has an
equivalent domain composition as ADAMTS-4-3 bound to
LRP1 with a KD,app of 65 nM. Further deletion of the TS1
domain (ADAMTS-5-5) abolished binding to LRP1. These
results indicate that ADAMTS-4 binds to LRP1 via its Sp and
CysR domains, whereas ADAMTS-5 binds to LRP1 via its Sp
and TS1 domains.
Expression and Purification of Soluble Recombinant LRP1
Fragments—The ligand binding regions in LRP1 occur in four
clusters (clusters I-IV) containing between 2 and 11 individual
ligand binding cysteine-rich repeats. Most of the ligands for
FIGURE 2. ADAMTS-4 is internalized and degraded by articular cartilage chondrocytes via LRP. A, live (L) and dead (D) porcine cartilage explants (n 3)
were incubated with 10 nM ADAMTS-4 (TS-4) for 0–8 h, and ADAMTS-4 in the media and cartilage explants was detected by Western blotting using an
anti-ADAMTS-4 catalytic domain antibody. B, densitometric analysis of immunoreactive ADAMTS-4 bands detected in the media of A or in the media of live
cartilage explants incubatedwith 10 nM ADAMTS-4 in the presence of 500 nM RAP for 0–8 h. The amount of ADAMTS-4was expressed as a% of the amount of
ADAMTS-4 at 0 h. C, porcine primary chondrocytes (n 3) were incubatedwith ADAMTS-4, and enzyme remaining in themediumwasmeasured as in B. Data
points represent the means  S.D. D, confocal microscopy analysis of ADAMTS-4 endocytosis by porcine chondrocytes. Cells were incubated with 20 nM
ADAMTS-4 (TS-4) in the presence or absence of 500 nM RAP or 100 g/ml heparin for 4 h. Endocytosed ADAMTS-4, EEA1, cytoskeleton, and nucleus were
visualized as described under “Experimental Procedures.”
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FIGURE 3. siRNA-mediated knockdownof LRP1 impairs ADAMTS-4 endo-
cytosis in human chondrocytes. Human chondrocytes (n 3) transfected
with non-targeting siRNA (siCtrl) or LRP1 targeting siRNA (siLRP1) were cul-
tured for 2 days in DMEM containing 10% FCS. A, results of TaqMan real-time
PCR showing relative levels of mRNA for LRP1. B, LRP1 -chain (515 kDa) and
-chain (85 kDa) in cell lysate were assessed by Western blotting using anti-
LRP1-chain (8G1) and-chain (5A6) antibodies, respectively.C, densitomet-
ric analysis of immunoreactive LRP1bands detected in B. The amount of LRP1
was expressed as a % of the amount of LRP1 in untransfected cells (None). D,
cells were incubatedwith 10 nMADAMTS-4 in the presence or absence of 500
nM RAP for 0–8 h, and ADAMTS-4 remaining in themediumwasmeasured as
in Fig. 2. Bars and points represent the means S.D.
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LRP1 for which the binding sites have been mapped interact
with ligand binding repeats in clusters II and IV (39). To further
investigate which ligand binding cluster of LRP1 interacts with
the two ADAMTS enzymes, we expressed four soluble clusters
of ligand binding repeats (clusters I-IV) in HEK293 cells, and
each fragmentwas purified from the conditionedmedia of tran-
siently transfected HEK293 cells by nickel-nitrilotriacetic acid
affinity chromatography. SDS-PAGE analysis of each cluster
with silver staining is shown in Fig. 7B. The purified proteins
were further verified by Western blot analysis using an anti-
Myc antibody (Fig. 7C). Approximately 30g of cluster I, 70g
of cluster II, 100 g of cluster III, and 30 g of cluster IV were
purified from 1 liter of conditioned medium. Treatment of
these clusters with N-glycosidase F produced a single band for
each fragment (Fig. 7D), indicating that the heterogeneity of
these preparations is due to different degrees ofN-glycosylation
(40).
Binding of ADAMTS-4 and ADAMTS-5 to LRP1 Clusters—
To identify the region(s) of LRP1 that binds to ADAMTS-4 and
ADAMTS-5, each recombinant clusterwas coated onmultiwell
plates, and subsequent binding of various forms of the enzyme
was quantified using an antibody against their C-terminal
FLAG tag. ADAMTS-4-1, ADAMTS-4-2, ADAMTS-5-2,
ADAMTS-5-3, and ADAMTS-5-4 were used in this study as
they showed affinity for full-length LRP1. Only limited experi-
ments were conducted with ADAMTS-4-1, as the amount of
pure form available is limited, but extrapolated apparent bind-
ing constants (KD,app) of 98 and 73 nMwere calculated for bind-
ing to immobilized clusters II and IV, respectively, whereas the
binding affinity of ADAMTS-4-1 to clusters I and III was very
low as no saturation was observed even at 200 nM (Fig. 8 and
Table 2). ADAMTS-4-2 bound to immobilized clusters II and
IV with KD,app values of 240 and 330 nM, respectively. On the
other hand, ADAMTS-5-2 bound to clusters II and IV with
high affinity, with KD,app values of 3.5 and 9 nM, respectively.
It also bound to cluster III with a KD,app of 41 nM. ADAMTS-
5-3 and -5-4 bound to cluster II with weaker affinity (KD,app
 80–120 nM).
ADAMTS-5 Competitively Inhibits Endocytosis of ADAMTS-4—
Because both ADAMTS-4-1 and ADAMTS-5-2 bind to clus-
ters II and IV, competition studies on endocytosis of these
enzymes were carried out. To address whether ADAMTS-4-1
and ADAMTS-5-2 competitively inhibit each other’s endocy-
tosis, 10 nM ADAMTS-4-1 or ADAMTS-5-2 was incubated
with porcine chondrocytes in the presence of an equimolar or
10-fold higher concentration of the other enzyme, and the level
of the enzyme in the medium was monitored by Western blot
analysis. The addition of 100 nM ADAMTS-5-2 markedly
reduced the rate of endocytosis of 10 nM ADAMTS-4-1 (Fig.
9A), suggesting that ADAMTS-5-2 can competitively inhibit
endocytosis of ADAMTS-4-1. On the other hand, the rate of
endocytosis of 10 nM ADAMTS-5-2 was not affected by the
presence of 100 nM ADAMTS-4-1 (Fig. 9B).
DISCUSSION
In this study we have demonstrated that ADAMTS-4 is
endocytosed by chondrocytes via LRP1. In our previous study
we did not recognize this phenomenon because the difference
between GAG release from live and dead cartilage was not
large. With further analysis, subtraction of the basal levels of
GAG release from live and dead cartilage allowed us to identify
that ADAMTS-4 is indeed endocytosed. Furthermore, our cur-
rent dose-dependent study indicated that the difference in
GAG release between live and dead cartilage is masked at high
concentrations of ADAMTS-4. Lowering the concentration of
ADAMTS-4 clearly demonstrated that 3–5-fold less GAG is
released from live cartilage compared with dead cartilage. Sub-
traction of the basal levels of GAG release from live and dead
cartilage also unmasked the significantly reduced GAG release
in live cartilage incubated with MMP-13 (data not shown),
which has previously shown to be endocytosed by chondrocytes
via LRP1 (28, 29). LRP1-mediated endocytosis is, therefore, a
newly discovered mechanism for regulating ADAMTS-4 activ-
ity in cartilage. Because LRP1 is widely expressed in a variety of
organs, we speculate that endocytic regulation of ADAMTS-4
activity occurs in various other tissues. The expression of
ADAMTS-4 and ADAMTS-5 mRNAs has been reported to
increase in human glioblastomas (41–43) andADAMTS-4, and
its proteolytic fragments differentially affect melanoma growth
and angiogenesis in mice (44). Interestingly, ADAMTS-4 pro-
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FIGURE 4. Inhibition of ADAMTS-4 endocytosis by RAP enhances aggrecan degradation in articular cartilage. A, time course of GAG released into the
mediumof live anddeadporcine cartilage explants (n3) incubatedwith 20nMADAMTS-4 in thepresenceor absenceof 500nMRAP.B, densitometric analysis
of immunoreactive bands of aggrecan fragments detected in the medium obtained after 24 h of culture in A by Western blotting using an anti-ARGSV
neoepitope antibody. The amount of aggrecan fragment in the medium of live cartilage explants incubated with 20 nM ADAMTS-4 was taken as 1. C, live and
dead human cartilage explants of normal patients (n  5) were incubated with 20 nM ADAMTS-4 in the presence or absence of 500 nM RAP for 24 h. GAG
released into the medium was measured by dimethylmethylene blue assay. Bars and points represent the means S.D. *, p	 0.05; unpaired t test.
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motes neurite outgrowth by cleaving proteoglycans, which con-
tributes to functional recovery after spinal cord injury (45).
Thus, LRP1-mediated endocytosis of ADAMTS-4 may play a
regulatory role in tumor malignancy and neurite outgrowth.
It is notable that the rate ofADAMTS-4 endocytosis is slower
than that of ADAMTS-5, with the half-lives of full-length
ADAMTS-4-1 and ADAMTS-4-2 (without the Sp domain)
being 2.2- and 1.6-fold longer than their ADAMTS-5 coun-
terparts. Internalization of ADAMTS-4-3 lacking the CysR and
Sp domains was essentially negligible, whereas ADAMTS-5-4
with the same domain composition was internalized with a
half-life of 250min. These observations can be explained by the
differences in affinity to sLRP1 among different forms of the
two ADAMTS enzymes. As shown in Table 1, ADAMTS-4 iso-
forms have much lower affinity compared with ADAMTS-5
counterparts. These results highlight that the rate of endocyto-
sis is regulated by the affinity of LRP1 for a particular ligand.
Studies using individual ligand binding clusters of LRP1 further
revealed that ADAMTS-4-1 binds to clusters II and IV with
similar affinity. ADAMTS-4-2 also binds to clusters II and IV
but with reduced affinity. These results suggest that the Sp and
CysR domains interact with clusters II and IV. However, the
affinity of ADAMTS-4-1 andADAMTS-4-2 for sLRP1 contain-
ing all four clusters is about 2-fold higher than that for binding
to cluster II and IV individually, indicating that these clusters
have an additive effect on ADAMTS-4 binding, although the
elucidation of the exactmode of interaction of ADAMTS-4 and
LRP1 needs structural studies. ADAMTS-5-2 (without the
C-terminal TS2 domain), a similar domain composition of
ADAMTS-4-1, binds to clusters II and IVwith a lownanomolar
KD,app value and to cluster III with a KD,app of 41 nM. The
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FIGURE 5. Sp and CysR domainsmediate ADAMTS-4 endocytosis. A, sche-
matic representation of ADAMTS-4, ADAMTS-5, and their domain deletion
mutants. Pro, prodomain; Cat, catalytic domain; Dis, disintegrin-like domain;
TS, thrombospondin domain; CysR, cysteine-rich domain; Sp, spacer domain.
B, porcine primary chondrocytes (n  3) were incubated with each 10 nM
ADAMTS-4-1, ADAMTS-4-2, ADAMTS-4-3, or ADAMTS-4-4 for 0–8 h, and
ADAMTS-4 and each ADAMTS-4 mutant remained in the medium was mea-
sured as in Fig. 2. C, as a comparison, porcine chondrocytes were incubated
with each 10 nMADAMTS-5-2, ADAMTS-5-3, ADAMTS-5-4, or ADAMTS-5-5 for
0–8 h, and ADAMTS-5 and each ADAMTS-5mutant remained in themedium
was measured as in B. Points represent the means S.D.
TABLE 1
Apparent half-life of ADAMTS-4, ADAMTS-5, and their domain dele-
tion mutants in the medium of chondrocytes and KD,app values for
their binding to LRP1
t1⁄2 and extrapolated KD,app values were estimated based on the results in Figs. 5
and 6.
Enzyme form t1⁄2 KD,app
nM
TS-4-1 220 51
TS-4-2 360 110
TS-4-3 480 1000
TS-4-4 480 1000
TS-5-1 NDa NDa
TS-5-2 100 3.8
TS-5-3 220 56
TS-5-4 250 65
TS-5-5 480 1000
a Both values for ADAMTS-5-1 were not determined as the full-length enzyme is
not available in a reasonable quantity due to rapid autodegradation.
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FIGURE 6. ADAMTS-4 and ADAMTS-5 directly bind to LRP1 via different
non-catalytic domains. Full-length LRP1 was coated onto microtiter plates,
and binding of ADAMTS-4-1 (0–200 nM), ADAMTS-4-2 (0–1M), ADAMTS-4-3
(0–1M), ADAMTS-4-4 (0–1M), ADAMTS-5-2 (0–75nM), ADAMTS-5-3 (0–0.6
M), ADAMTS-5-4 (0–0.6M), or ADAMTS-5-5 (0–1M) in thepresence of 100
MCT-1746wasmeasuredusinganM2anti-FLAGantibodyandahorseradish
peroxidase-conjugate secondary antibody as described under “Experimental
Procedures.”
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domain deletion studies ofADAMTS-5 indicated that the bind-
ing of ADAMTS-5 to LRP1 is primarily mediated by the Sp
domain, whereas the TS1 domain also binds but with a signifi-
cantly reduced affinity. The LRP1 ligands that binds to cluster
III reported so far are apolipoprotein E (46) and RAP, which
binds to all clusters (38). ADAMTS-5 is another example that
can bind to cluster III through its Sp domain, although clusters
II and IV provide the major binding sites for ADAMTS-5
through the Sp domain (KD,app  3.5 and 9 nM, respectively).
The TS1 domain binds to clusters II and IV, but more weakly.
Endocytosis competition studies betweenADAMTS-4-1 and
ADAMTS-5-2 reveled that, although we originally anticipated
that a 1:1 molar ratio of ADAMTS-5 and ADAMTS-4 would
have an inhibitory effect on full-length ADAMTS-4 endocyto-
sis due to the higher affinity of ADAMTS-5-2 for LRP1, a
10-fold higher concentration of ADAMTS-5 was necessary to
see significant inhibition of ADAMTS-4 internalization. A
higher concentration of ADAMTS-5-2 was probably required
because of its rapid cellular uptake during incubation. On the
other hand, the rate of endocytosis of ADAMTS-5 was not
affected by the presence of ADAMTS-4, which is likely to be
due to the much lower affinity of ADAMTS-4 for LRP1. These
results suggest that LRP1 is a major traffic controller of the two
aggrecanases under inflammatory conditionswhere the protein
levels of ADAMTS-4 increase but those of ADAMTS-5 do not
(for review, see Ref. 47). Furthermore, it could be possible that
ADAMTS-5 can rescue other LRP1 ligands with lower affinity
to LRP1; for instance, tissue-type plasminogen activator
(KD,app 158 nM), plasminogen activator inhibitor-1 (KD,app
35 nM) (40), urokinase-type plasminogen activator (KD,app 60
nM) (48), pro-MMP-2 (KD,app 350 nM), TIMP-2 (KD,app 660
nM), proMMP-2/TIMP-2 complex (KD,app  50 nM) (49), and
MMP-9/TIMP-1 complex (KD,app 20 nM) (50). On the other
hand, RAPhas been reported to inhibit the binding of all known
ligands to LRP1 not only by stearic hindrance of the LRP1
ligands but also by inducing conformational change in the LRP1
molecule (40, 51). The binding of ADAMTS-4 andADAMTS-5
to LRP1 could also be completely inhibited by the addition of an
excess of RAP; our estimate of aKD,app for RAP binding to LRP1
was determined to be 2 nM (data not shown), which is consis-
tent with a previous report (52).
The importance of basic residues for the interaction with
LRP1 has been shown for many protein ligands (27). We thus
postulate that basic residues in these domains are responsible
for LRP1 binding.We previously reported that heparin inhibits
endocytosis of ADAMTS-5 (36), and we found this is also the
A B
Ligand binding repeat
EGF repeat
β-propeller domain
Transmembrane domain
Cytoplasmic domain
Myc tag
His tag
C D
I
250
130
95
72
55
36
28
(kDa)
←
←
←
←
←
←
←
II III IV
I
250
130
95
72
55
36
28
(kDa)
←
←
←
←
←
←
←
II III IV
- PNGase F
250
130
95
72
55
36
28
(kDa)
+ - + - + - +
I II III IV
←
←
←
←
←
←
←
←
←
←
←
*
*
*
*
*
*
* * *
LRP1
Cluster I
Cluster II
Cluster III
Cluster IV
I II III IV
FIGURE7.Expressionandpurificationof soluble recombinantLRP1 fragments.A,modulardomainorganizationof LRP1and its soluble receptor fragments
used in this study. The four clusters of ligand-binding clusters are numbered I-IV. The symbols for the various domains are indicated in the inset. B, SDS-PAGE
of LRP1 fragments containing each ligand binding cluster purified from conditioned medium of HEK293 cells transfected with the designated LRP1 clusters.
Proteinswere separatedona4–12%gelunder reducingconditions and stainedwith silver.C, purifiedproteinswere further analyzedbyWesternblottingusing
an anti-Myc antibody. D, Western blotting of each clusters before () and after (
) peptide N-glycosidase F (PNGase F) treatment. Proteins were probed by
anti-Myc antibody. The recombinant LRP1 fragments are indicated by the arrows, and asterisks indicate possible dimer or oligomer of the fragments.
Interaction between Aggrecanases and LRP1
6470 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 10•MARCH 7, 2014
 at RO
Y
A
L V
ET CO
LL./LIBRA
RIA
N
 on July 5, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
case for ADAMTS-4. Furthermore, heparin inhibits binding of
both enzymes to LRP1. As heparin binds to ADAMTS-4 and
ADAMTS-5 (53, 54), heparin may mask binding sites of these
enzymes to LRP1. On the other hand, the CysR and Sp domains
of ADAMTS-4 and ADAMTS-5 play an important role in reg-
ulating both proteolytic activity and localization of the enzyme
(9, 55). The deletion of the Sp domain results in release of
ADAMTS-4 from ECM (11). The deletion of the Sp domain
from ADAMTS-4 results in only a 5% of the original aggreca-
nase activity (11) and that from ADAMTS-5 results in 50% and
only 1% of the original activity at the interglobular domain and
chondroitin sulfate region 2 of aggrecan, respectively (10). Fur-
ther deletion of the CysR domain resulted in a further 75–99%
reduction in the activity (10). ADAMTS-4 undergoes C-termi-
nal cleavage at Lys694-Phe695 and Thr581-Phe582, respectively,
to generate truncated forms of 40 and 53 kDa. The 53-kDa form
lacks most of the Sp domain, and the 40-kDa form lacks the Sp
and most of the CysR domains (53). The C-terminal cleavage
events could be a result of autoproteolytic cleavage or due to the
action of other MMPs such as the MMP-17 (MT4-MMP) (53,
56). C-terminal processing of the full-length ADAMTS-4 has
been also reported in synovium and cartilage (15, 57–59).
Recently, Rao et al. (44) reported that proteolytic fragments of
ADAMTS-4 containing only the C-terminal non-catalytic
domains are found in cultured cells and human cancer tissues
and suppress melanoma cell growth and angiogenesis in mice.
Thus, processing of these domains is likely to have a large
impact on the function and trafficking of ADAMTS-4 in vivo.
An alternatively splicedADAMTS-4mRNA lackingmost of the
Sp domain but instead encoding a new unrelated C-terminal
sequence is found in human synovium from OA patients (60,
61). As this form lacksmost of the Sp domain, the uptake rate of
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FIGURE 8. Binding of ADAMTS-4 and ADAMTS-5 to LRP1 clusters. Purified
LRP1 fragmentswere coated ontomicrotiter plates, and binding of ADAMTS-
4-1 (0–0.2M), ADAMTS-4-2 (0–1M), ADAMTS-5-2 (0–0.2M), ADAMTS-5-3
(0–1 M), or ADAMTS-5-4 (0–1 M) was measured as in Fig. 6.
TABLE 2
KD,app values for binding of ADAMTS-4-2, ADAMTS-5-2, ADAMTS-5-3,
and ADAMTS-5-4 to LRP1 fragments
Extrapolated KD,app values were estimated based on the results in Fig. 8.
Enzyme form
KD,app
Cluster I Cluster II Cluster III Cluster IV
nM
TS-4-1  200 98 100 73
TS-4-2  1000 200 500 260
TS-5-2  200 3.5 41 9
TS-5-3  1000 80 500 325
TS-5-4  1000 120 500 340
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FIGURE 9. ADAMTS-5 competitively inhibits ADAMTS-4 endocytosis. A,
porcine primary chondrocytes (n 3) were incubated with 10 nM ADAMTS-
4-1 plus 100 M CT-1746 in the presence of 500 nM RAP, 10 nM ADAMTS-5-2
(TS-4/TS-5 (1:1)), or 100 nM ADAMTS-5-2 (TS-4/TS-5 (1:10)) for 0–8 h, and
ADAMTS-4-1 remaining in the medium was measured as in Fig. 2. B, the
experiment was carried out as in A using 10 or 100 nM ADAMTS-4-1 as a
competitor against 10 nM ADAMTS-5-2, and ADAMTS-5-2 remaining in the
medium was measured as in Fig. 2. Data represent the means S.D.
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the enzyme by the cells might be slower than that of the wild-
type enzyme.
ADAMTS-4 and ADAMTS-5 have been implicated in the
development of OA (for review, see Ref. 47). Our present and
recent studies demonstrated that normal human articular car-
tilage internalizes both ADAMTS-4 and ADAMTS-5, but this
process was not observed with OA cartilage (17). A similar
observationwas reported forMMP-13without alteration in the
mRNA levels of LRP1 (29). We confirmed that there are no
changes in the LRP1mRNA between normal and OA cartilage,
but found that LRP1 protein was greatly diminished in OA car-
tilage (17). We, therefore, proposed that the ectodomain of
LRP1 is shed from the cell membrane of OA chondrocytes,
thereby reducing the endocytic capacity of the cell. LRP1 shed-
ding is increased in malignant cells (62, 63) and under inflam-
matory conditions such as in rheumatoid arthritis and systemic
lupus erythematosus (64). We recently reported that the shed
soluble LRP1 (sLRP1) forms a complex with TIMP-3 and pro-
tects the inhibitor from endocytosis, and the sLRP1-TIMP-3
complex retains inhibitory activity against ECM-degrading
metalloproteinases (30). sLRP1 also binds to ADAMTS-4,
ADAMTS-5, andMMP-13, but the consequences of this inter-
action on their activity are not known. It is, therefore, impor-
tant to investigate the activities of thesemetalloproteinases and
TIMP-3 that are in complex with sLRP1. We have mapped
LRP1 binding sites in ADAMTS-4 to the C-terminal Sp and
CysR domains and those in ADAMTS-5 to the Sp and TS1
domains. These domains are key for the enzyme interaction
with aggrecan (9, 10). sLRP1 ismost likely to bind toMMP-13 at
the opposite site from the active site where a large positive area
distributes (65). Therefore, the binding of sLRP1 to those met-
alloproteinases may alter their activity for their ECM sub-
strates. In addition, it may also alter their binding to sulfated
components of the ECM and their location in the extracellular
space. We speculate that an increase in LRP1 shedding alters
the trafficking of key ECM-degrading enzymes and their inhib-
itor TIMP-3. Such changes appear to shift the homeostatic bal-
ance of ECM turnover toward the catabolic side. This is evident
from an overall increase in aggrecan degradation in normal car-
tilage by the addition of RAP. Thus, even a small shift in the
proteolytic balancemay be sufficient to initiate slowly progress-
ing and chronic disease.
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